trial

A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)

NCTId NCT02694328
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 561 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2018-11-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
561 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-03-02
Primary completion
2018-11-07
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ALKS 3831Olanzapine

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

54 total
Little Rock, United StatesSpringdale, United StatesAnaheim, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLong Beach, United StatesNational City, United StatesOakland, United StatesOceanside, United StatesOrange, United States

Linked catalysts

1
A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) — primary completion2018-11-07

Facts & assertions

4 sourced
Enrollment
561
Phase
PHASE3
Primary Completion Date
2018-11-07
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 3831
drug
Olanzapine
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Body Weight
indication
investigator
Alkermes Medical Director, MD
person